Association between the CYP3A4 and CYP3A5 polymorphisms and cancer risk: a meta-analysis and meta-regression
Authors:
- 4 July 2014
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 35 (10) , 9859-9877
Abstract
Previously published data on the association between CYP3A4 A392G and CYP3A5 Met235Thr polymorphisms and the risk of cancer remained controversial. Thus, we performed a meta-analysis to investigate the association between cancer susceptibility and CYP3A4 A392G (18,629 cases and 22,323 controls from 49 studies) and CYP3A5 Met235Thr polymorphisms (14,334 cases and 18,183 from 39 studies) in different inheritance models. We used odds ratios with 95 % confidence intervals to assess the strength of the association. Overall, significant association was found between CYP3A4 A392G polymorphism and cancer susceptibility (dominant model, odds ratio (OR) = 1.19; 95 % confidence interval (CI) = 1.03–1.38). In the further stratified and sensitivity analyses, significant increased prostate cancer risk was found among Caucasians (dominant model, OR = 1.88; 95 % CI = 1.20–2.95; recessive model, OR = 2.10; 95 % CI = 1.23–3.60; additive model, OR = 1.80, 95 % CI = 1.24–2.63; homozygous model, OR = 2.34, 95 % CI = 1.36–4.03; heterozygote model, OR = 1.79, 95 % CI = 1.11–2.89) for CYP3A4 A392G. For CYP3A5 Met235Thr polymorphism, no significant association was found among overall analysis and any subgroup analysis. In summary, this meta-analysis suggests that CYP3A4 A392G polymorphism is associated with increased prostate cancer risk among Caucasians and CYP3A5 Met235Thr polymorphism is not associated with the risk of cancer.Keywords
This publication has 69 references indexed in Scilit:
- Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese MenProstate Cancer, 2012
- Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patientsBritish Journal of Clinical Pharmacology, 2011
- Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer RiskAmerican Journal of Epidemiology, 2009
- African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancerCancer Epidemiology, 2009
- Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genesCarcinogenesis, 2008
- Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF‐1, and IGFBP‐3 and prostate cancer risk in African‐American men: The Flint Men's Health StudyThe Prostate, 2007
- Genetic variability in CYP3A4 and CYP3A5in primary liver, gastric and colorectal cancer patientsBMC Cancer, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003
- P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclaturePharmacogenetics, 1996
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986